Tom Wilemon

Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.

Vanderbilt researchers have received $5 million in funding from a new initiative by the National Cancer Institute that aims to define how gastric and gastroesophageal junction adenocarcinomas form and evolve at the cellular level.

Chic Awearness, a fundraiser for ovarian cancer research at Vanderbilt-Ingram Cancer Center (VICC), is an online event this year from now throughout September with an in-store shopping opportunity to close out the month called Chic Week.

Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.

Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.